Adrian Kinkaid Acquires 100,000 Shares of Fusion Antibodies plc (LON:FAB) Stock

Fusion Antibodies plc (LON:FAB) insider Adrian Kinkaid acquired 100,000 shares of Fusion Antibodies stock in a transaction on Tuesday, May 6th. The shares were bought at an average cost of GBX 6 ($0.08) per share, for a total transaction of £6,000 ($7,976.60).

Fusion Antibodies Trading Down 3.3 %

FAB opened at GBX 5.90 ($0.08) on Thursday. The company has a debt-to-equity ratio of 2.40, a quick ratio of 2.36 and a current ratio of 3.87. The stock’s 50 day moving average price is GBX 6.79 and its 200-day moving average price is GBX 6.73. Fusion Antibodies plc has a one year low of GBX 2.80 ($0.04) and a one year high of GBX 12 ($0.16). The stock has a market cap of £5.55 million, a price-to-earnings ratio of -1.33 and a beta of 0.49.

Fusion Antibodies Company Profile

Fusion is a Belfast based contract research organisation (“CRO”) providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.

The Company’s ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation.